GT Biopharma appoints Manu Ohri as CFO, replacing Gavin Choy as Acting CFO

GT Biopharma, Inc.

Manu Ohri appointed CFO effective Feb 14, 2022; Gavin Choy ceases as Acting CFO.
Annual base salary of $325,000; target bonus up to 40% of base salary.
Stock award of 25,000 shares and option to purchase 175,000 shares vesting over 3 years.
Options fully accelerate upon a change of control; employment agreement to be signed.
Ohri is a CPA with prior CFO experience at ToughBuilt Industries and Big 4 background.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Manu Ohri

Chief Financial Officer

GTBP · GT Biopharma, Inc.

Effective: 2022-02-14
Filed: February 18, 2022, 6:59 PM ET

Effective February 14, 2022, the Registrant appointed Manu Ohri as the Registrant’s Chief Financial Officer

Departed

Gavin Choy

Acting Chief Financial Officer

GTBP · GT Biopharma, Inc.

Effective: 2022-02-14
Successor: Manu Ohri
Filed: February 18, 2022, 6:59 PM ET

Gavin Choy ceased serving as the Registrant’s Acting Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Manu Ohri was appointed as Chief Financial Officer at GT Biopharma, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective February 14, 2022, the Registrant appointed Manu Ohri as the Registrant’s Chief Financial Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Gavin Choy departed as Acting Chief Financial Officer at GT Biopharma, Inc..

Action: ceased serving
Role: Acting Chief Financial Officer

Exact text from the filing

Gavin Choy ceased serving as the Registrant’s Acting Chief Financial Officer.

View on SEC.gov

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-22-001828

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.